Jonathan Friedberg
@DrJFriedberg
Lymphoma expert. Director of @WilmotCancer Rochester NY. Editor-in-Chief, Journal of Clinical Oncology @asco_pubs. Tweets and opinions are my own.
ID:2886201454
http://www.urmc.rochester.edu/people/20880804-jonathan-w-friedberg 20-11-2014 21:50:17
2,0K Tweets
5,3K Followers
402 Following
Prevalence and Cancer-Specific Patterns of Functional Disability Among US Cancer Survivors: over a quarter of reported mobility disability, and nearly 10% reported self-care disability. Journal of Clinical Oncology
ascopubs.org/doi/full/10.12…
Treatment with Adcetris plus chemotherapy or Opdivo was demonstrated as a “promising” option for patients with classical #HodgkinLymphoma , according to Dr. Jonathan W. Friedberg (Jonathan Friedberg) of Wilmot Cancer Institute and UR Medicine.
Read more: curetoday.com/view/-promisin…
Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: mosunetuzumab can mediate durable remissions with time-limited treatment
Journal of Clinical Oncology ascopubs.org/doi/full/10.12…
Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richters: These results suggest a proportion of patients derive benefit from CAR-T therapy and emphasize the importance of future prospective trials Journal of Clinical Oncology ascopubs.org/doi/full/10.12…
New findings show adult #cancer treatment trial participation nationally is 7.1% and >20% of pts contribute to any type of cancer study. Clinical research is a true partnership between #patients and researchers Mark Fleury Fred Hutchinson Cancer Center ascopubs.org/doi/10.1200/JC…
International Prognostic Score for Nodular Lymphocyte–Predominant Hodgkin Lymphoma: important work by my Wilmot Cancer Institute colleague Jamie Flerlage Journal of Clinical Oncology
ascopubs.org/doi/full/10.12…
'Failing Forward in Peripheral T-Cell Lymphoma' : thoughtful Journal of Clinical Oncology commentary on future clinical trial directions in this disease by Drs. Horwitz and Neha Mehta-Shah
ascopubs.org/doi/full/10.12…
excited to share an episode of the Journal of Clinical Oncology Podcast where I discuss updates of the LYSA and RESORT trials; these long-term outcomes and updates from these studies cement the standard set out by these studies for MCL and FL and continue to do so! ASCO
sites.libsyn.com/58526/jco-arti…
Thoughtful editorial by Dr. Radford on newly appreciated Doxorubicin and Breast Cancer Risk, emphasizing importance of Long-Term Follow-Up in Curable Cancers Journal of Clinical Oncology ascopubs.org/doi/full/10.12…
Spatially Resolved Tumor Microenvironment Predicts Treatment Outcomes in Relapsed/Refractory Hodgkin Lymphoma: future studies should validate this in patients treated with checkpoint blockade. Journal of Clinical Oncology
ascopubs.org/doi/full/10.12…
Chronic Lymphocytic Leukemia: survivorship model of care provides an opportunity to deliver a multidisciplinary and holistic approach to optimize outcomes. Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…
The Power of Story: insightful thoughts and a moving piece. Journal of Clinical Oncology ascopubs.org/doi/full/10.12…
Proud that the majority of Wilmot Cancer Institute executive committee and program leaders are women.
Impact of Helicobacter pylori Infection and Treatment on Colorectal Cancer in a Large, Nationwide Cohort: a very provocative observation. Journal of Clinical Oncology
ascopubs.org/doi/abs/10.120…
Thanks to Ryan Lynch for an excellent commentary on our Blood Journal manuscript evaluating BV combinations in older patients with HL, moving toward a cure for cHL without chemotherapy ashpublications.org/blood/article/…
Improving Rural Clinical Trial Enrollment: Recommendations From the Rural Health Working Group of the Alliance Clinical Trials Network. Journal of Clinical Oncology
ascopubs.org/doi/full/10.12…